From clinical efficacy to population health: Implementing vonoprazan-amoxicillin dual therapy for Helicobacter pylori control

Abstract

Helicobacter pylori (H. pylori) infection remains a significant global health challenge, necessitating effective, simple, and scalable eradication strategies. This editorial evaluates vonoprazan-amoxicillin (VPZ-AMO) dual therapy from clinical, public health, and health-economic perspectives, based on evidence from a recent large-scale, multi-center randomized controlled trial. The trial demonstrated that a 14-day VPZ-AMO dual regimen, particularly with amoxicillin administered at 0.5 g four times daily, achieves excellent eradication rates, outstanding safety, and high compliance. Given this compelling clinical profile, the regimen transcends a mere therapeutic option and emerges as a potential public health tool. Its advantages include significant cost-effectiveness compared to bismuth-containing quadruple therapy, high adherence due to dosing simplicity, and minimal transient impact on the gut microbiota. These features position it as a cornerstone candidate for large-scale screening and eradication programs aimed at reducing the burden of gastric cancer. Successful population-level implementation, however, requires addressing key challenges such as strengthening antimicrobial resistance surveillance, ensuring equitable access, and building healthcare system capacity. With scientifically grounded and proactively executed strategies, VPZ-AMO dual therapy holds substantial promise as a potential key intervention against H. pylori in high-prevalence regions over the coming decade.

Key Words: Helicobacter pylori; Vonoprazan; Amoxicillin; Dual therapy; Eradication treatment; Public health; Pharmacoeconomics; Antibiotic resistance

Core Tip: This editorial highlights vonoprazan-amoxicillin dual therapy, particularly the 0.5 g four-times-daily regimen, as a highly effective, safe, and well-tolerated strategy for Helicobacter pylori eradication, based on a recent large-scale regional trial. Its exceptional cost-effectiveness, high patient compliance, and dosing simplicity position it as a transformative candidate for large-scale public health interventions that aimed at reducing the burden of Helicobacter pylori-associated diseases, including gastric cancer. Successful implementation, however, necessitates addressing challenges such as antimicrobial resistance surveillance and ensuring equitable access to healthcare systems.

INTRODUCTION

Helicobacter pylori (H. pylori) infection represents a significant global public health challenge. A systematic review and meta-analysis of data from 2011 to 2022 estimated its worldwide prevalence at 43.1%[1]. In mainland China, the overall prevalence is 44.2%, with significantly higher rates observed in specific regions, notably, northwestern (51.8%), eastern (47.7%), and southwestern (46.6%) China[2]. Despite this substantial disease burden, the precise mechanisms, modes of transmission, and associated behavioral factors that facilitate its widespread distribution are not yet fully understood. Consequently, addressing the epidemiological burden and associated clinical challenges is an urgent priority. Persistent infection with this gram-negative bacterium is implicated not only in chronic active gastritis but also serves as a well-established risk factor for peptic ulcers, gastric mucosa-associated lymphoid tissue lymphoma, and gastric cancer. Furthermore, emerging evidence suggests a potential association with colorectal cancer[3]. Gastric cancer itself ranks as the fifth most commonly diagnosed cancer and the third leading cause of cancer-related mortality worldwide[4]. Notably, H. pylori infection is classified by the World Health Organization as a group 1 carcinogen. It is recognized as the primary etiological agent in approximately 70% of gastritis cases, and regions with high H. pylori prevalence consistently demonstrate a significantly increased incidence of gastric cancer[5]. Consequently, suppressing H. pylori infection is widely considered a pivotal strategy for gastric cancer prevention, with antimicrobial therapy constituting a primary preventive measure.

Current eradication therapies for H. pylori face substantial challenges. The efficacy of traditional dual therapies involving proton pump inhibitors (PPIs) and clarithromycin, as well as standard triple therapies comprising amoxicillin (AMO), clarithromycin, and a PPI, has declined globally, a trend largely attributable to rising rates of clarithromycin resistance[6]. Surveillance data from Australia indicate that the average rate of clarithromycin resistance has exceeded 20% since 2010, with more than 25% of isolates demonstrating resistance in recent years[7]. Although bismuth-containing quadruple therapy (BQT) is widely recommended as an alternative regimen, its complex dosing schedule often compromises patient adherence, and its relatively high incidence of adverse effects limits its applicability in large-scale public health initiatives[8]. Compounding this issue, over one billion people worldwide lack access to bismuth-based treatments. This therapeutic gap is particularly acute in regions and primary care settings where bismuth preparations are unavailable, underscoring an urgent need for novel strategies that are effective, safe, and simple to administer[9].

MECHANISM OF ACTION AND CLINICAL EVIDENCE FOR VONOPRAZAN-AMO DUAL THERAPY

Vonoprazan (VPZ), a next-generation potassium-competitive acid blocker (P-CAB), exhibits pharmacological properties superior to those of conventional PPIs. Its unique advantages include: A high acid dissociation constant (pKa) of 9.6, which ensures stability in the highly acidic environment of the parietal cell secretory canaliculus[10]; insensitivity to CYP2C19 genetic polymorphisms, providing consistent pharmacodynamic effects across different metabolic phenotypes; and critically, the ability to maintain an intragastric potential of hydrogen (pH) > 4 for over 90% of a 24-hour period (mean 24-hour intragastric pH > 4 holding time ratio), thereby establishing an optimal microenvironment for AMO to exert its maximal antibacterial activity[11].

A recent multicenter randomized controlled trial by Wu et al[12], published in the World Journal of Gastroenterology, provides key evidence supporting the clinical application of VPZ-AMO dual therapy. This multi-center trial, conducted at 17 hospitals in Sichuan Province, China, enrolled 1717 patients to compare the efficacy and safety of three VPZ-AMO dosing regimens. These regimens differed primarily in AMO dose and frequency: 0.5 g four times daily, 0.75 g four times daily, and 1.0 g three times daily. All three achieved consistently high eradication rates in both intention-to-treat and per-protocol analyses. The lowest-dose, most frequent regimen (0.5 g q.d.s.) demonstrated a comparatively favorable safety profile across age groups, with a low overall incidence of adverse events. Nevertheless, several methodological limitations warrant attention. First, the open-label trial design and lack of detailed blinding procedures introduce a potential for performance bias, despite the use of an objective primary endpoint including ¹³C-urea breath test (UBT). Second, as all participating centers were located within a single Chinese province, the generalizability of the findings is geographically constrained. Future validation across diverse regions (e.g., other provinces and countries) and populations (e.g., individuals of European or African ancestry) is essential to confirm its broad applicability. Furthermore, the study did not include dynamic antimicrobial resistance surveillance. Although current evidence remains limited and geographically specific, emerging reports provide early signals that warrant careful monitoring. For instance, a Japanese surveillance study documented a rise in the primary resistance rate of H. pylori clinical isolates to AMO from 1.6% during 2002-2005 to 2.7% in 2018-2020[13]. While this increase is modest and derived from a specific national context, it serves as a crucial early indicator of a potential trend. This trend underscores the necessity of establishing long-term, systematic resistance monitoring networks and advancing susceptibility-guided precision treatment strategies.

From a pharmacodynamic perspective, the antibacterial efficacy of AMO is optimized by maximizing the duration for which its plasma concentration remains above the minimum inhibitory concentration (MIC), a principle known as time-dependent killing. Therefore, the strategic advantage of the 0.5 g four-times-daily regimen lies in its increased administration frequency, which helps maintain more consistent plasma drug levels and thereby prolong the time above MIC. This pharmacodynamic rationale is supported by in vitro studies demonstrating the marked bactericidal effects of AMO against various clinically isolated H. pylori strains[14]. Clinically, this principle is further reinforced by studies such as that of Li et al[15], which suggested that increasing the frequency of AMO administration may improve eradication rates more effectively than raising the dose per administration. Together, these findings highlight that sustaining time above MIC appears more critical for efficacy than achieving high peak concentrations. This understanding informed the design of a recent national randomized controlled trial that directly compared dosing schedules. Consistent with the pharmacological premise, the trial demonstrated the non-inferiority of a lower total daily dose (2 g administered twice daily) compared to a higher dose (3 g three times daily), supporting the adequacy of the lower-dose regimen within the VPZ-AMO dual therapy framework[16].

PUBLIC HEALTH VALUE AND IMPLEMENTATION STRATEGIES FOR VPZ-AMO THERAPY

From a public health perspective, the VPZ-AMO dual therapy demonstrates multiple advantages. In terms of health economics, the regimen demonstrates significant structural cost advantages. The study by Wu et al[12], which provides the core evidence for this editorial underscores this point, showing an approximately 46% reduction in cost per treatment course compared with BQT. This finding is corroborated by other randomized controlled trials that have consistently reported the superior cost-effectiveness of VPZ-AMO dual therapy over BQT[17-19]. Furthermore, the economic value of VPZ-AMO extends beyond direct comparison with BQT. A comprehensive literature review indicates that VPZ is superior to PPIs in efficacy, safety, and cost-effectiveness for both H. pylori eradication and reflux disease management[20]. The potential economic implications are substantial, especially in high-prevalence regions. Given an estimated 589 million individuals with H. pylori infection in China alone, widespread adoption of a cost-effective regimen such as VPZ-AMO could yield considerable savings in healthcare expenditure at the population level[21].

It is important to acknowledge that absolute cost savings may vary with regional drug procurement practices, national insurance policies, and across different healthcare systems. However, the inherent structural advantages of the dual therapy, such as fewer drug components, higher patient adherence, and lower adverse event rates, underpin its long-term cost-effectiveness. Besides, this economic advantage is likely attributable to several factors: The reduced number of drug types directly lowers medication acquisition costs and administrative complexity; Higher patient adherence minimizes follow-up expenses associated with retesting, second-line treatments, and complication management due to initial eradication failure; And the lower overall incidence of adverse events reduces indirect healthcare burdens[22].

The simplicity of the VPZ-AMO regimen makes it particularly suitable for implementation in primary care settings. A two-drug regimen is easier for primary care physicians to manage and for patients to adhere to. Research confirms that simplified dosing and a reduced side-effect profile significantly enhance treatment adherence, a critical factor for the success of large-scale public health programs[23,24]. A meta-analysis encompassing 668 patients with H. pylori infection reported a significantly lower incidence of adverse events (19.1%) with VPZ-AMO dual therapy compared with various triple therapies, underscoring its suitability for long-term, large-scale application[25-27].

Nevertheless, several critical issues require attention during the implementation of VPZ-AMO dual therapy for H. pylori eradication. First, it is essential to establish a comprehensive antimicrobial resistance surveillance network to regularly monitor trends in AMO resistance. Drawing on the experience of the European Helicobacter and Microbiota Study Group, we recommend establishing national or regional resistance surveillance systems that periodically publish resistance data to inform clinical prescribing practices. Second, diagnostic capacity in primary care settings must be strengthened to ensure the broad availability of confirmatory tests. To guide clinical practice effectively, the selection of diagnostic tests should prioritize clinical appropriateness. UBT is the preferred non-invasive method for confirming eradication, owing to its high accuracy. Monoclonal stool antigen tests provide a reliable alternative, particularly in settings where UBT is unavailable. Tests for serum IgG antibodies against H. pylori can be useful for screening in specific clinical contexts, such as in cases of bleeding peptic ulcers, gastric mucosa-associated lymphoid tissue lymphoma, and gastric cancer, but they do not indicate an active infection due to the persistence of antibodies. Finally, systematic patient follow-up and management protocols should be implemented. These should actively utilize medication education and adverse event intervention strategies to enhance adherence and ensure treatment quality. A core principle is that all patients must undergo confirmatory testing after eradication therapy. Subsequent management should be stratified based on individual gastric mucosal pathology risk, as assessed by the Operative Link for Gastritis Assessment/Operative Link on Gastric Intestinal Metaplasia Assessment staging systems. Patients classified as low-risk may require only clinical follow-up, whereas high-risk individuals such as those with advanced atrophic gastritis or a history of early gastric cancer must enter a structured endoscopic surveillance program. This risk-adapted approach is fundamental to the secondary prevention of gastric cancer[28].

FUTURE RESEARCH DIRECTIONS AND IMPLEMENTATION CHALLENGES

Although VPZ-AMO dual therapy shows considerable potential, several important issues require further investigation. First, given the high background prevalence of H. pylori in endemic areas, where recrudescence and re-infection may contribute significantly to the overall infection burden, longer-term follow-up studies in diverse populations are needed to evaluate the regimen’s impact on recurrence, recrudescence, and re-infection rates[29]. Such studies should employ multinational, multicenter designs enrolling participants from varied ethnic backgrounds to validate the regimen’s generalizability. Second, future trials should implement double-blind, randomized controlled designs to minimize the risk of bias. Sample sizes need to be expanded substantially, potentially to very large-scale trials, to detect rare adverse events and efficacy differences within patient subgroups. Third, the safety and efficacy of VPZ-AMO dual therapy in special populations such as the elderly, children, and pregnant women warrant dedicated evaluation. Furthermore, future research should investigate the multi-level impact of this regimen on the gut microbiota and explore whether its therapeutic efficacy can be enhanced through adjunctive strategies, such as the co-administration of probiotics. The potential role of fecal microbiota transplantation (FMT) also warrants exploration, although it is crucial to note that current evidence supporting FMT in this specific context remains preliminary and is primarily derived from small-scale studies[30,31]. Adding to this evidence base, a comprehensive multi-omics study by Hu et al[16], focused specifically on VPZ-AMO dual therapy, has provided reassuring data. The findings indicate that the low-dose AMO (2 g daily) regimen in particular induces only minimal and largely reversible perturbations to the gut microbiota and resistome. This further alleviates a major concern regarding its potential for large-scale application[15].

Key challenges to implementation include limited drug accessibility[32], disparities in medical insurance reimbursement policies[33], and unequal distribution of medical resources across regions[34]. To address these barriers, a phased and differentiated implementation strategy is recommended. Initial demonstration projects in high-prevalence regions could generate practical experience and build confidence. Subsequently, price negotiations for inclusion in national or regional health insurance schemes should be pursued to enhance affordability. Finally, establishing a nationwide or regional quality control framework is essential to standardize treatment protocols and ensure consistent therapeutic outcomes.

A critical limitation to the widespread implementation of VPZ-AMO dual therapy is its contraindication in patients with penicillin allergy. Epidemiological studies indicate that self-reported penicillin allergy affects approximately 5.9%-16.7% of the general population[35,36]. While a significant proportion of these reports may be invalidated upon professional evaluation, this perception nonetheless excludes a substantial patient subset from this regimen at the outset[37]. Consequently, implementing a standardized protocol for penicillin allergy screening prior to treatment initiation is paramount. For patients with confirmed or highly suspected allergy, alternative eradication regimens such as BQT or fluoroquinolone-containing triple therapy should be employed considering local resistance patterns[28]. From a public health perspective, large-scale eradication programs must therefore integrate capacity for allergy screening and ensure a reliable supply of alternative medications to guarantee equity and accessibility.

CONCLUSION

The evidence presented, particularly for the VPZ-AMO dual regimen, establishes P-CAB-AMO dual therapy as a promising new approach to H. pylori eradication. Its proven efficacy and favorable safety profile, coupled with the aforementioned advantages in patient adherence and cost-effectiveness, position it as a strong candidate for translation from a clinical option into a broader public health intervention. Moving forward, we recommend coordinated efforts across three domains. At the policy level, P-CAB-AMO dual therapy should be incorporated into national guidelines, supported by corresponding regulatory and financing policies. At the implementation level, integrated hospital-community H. pylori management networks should be established. At the research level, ongoing real-world effectiveness studies and health economic evaluations are essential. Through these comprehensive measures, significant progress can be anticipated in the management and control of H. pylori infection over the next decade, supporting the overarching public health goal of reducing the burden of gastric cancer.